Case Studies

Learn how MaxCyte's field applications scientists accelerate preclinical development for our cell therapy partners, ensuring that life-saving therapies reach patients when needed.

At MaxCyte, we understand the intricate journey of cell therapy development, and our commitment to our partners' success is at the heart of our business model. We go above and beyond to build trust with our customers and ensure that life-saving therapies reach patients when they need them most.

Our team of field applications scientists plays a pivotal role in this mission. Armed with our clinically proven electroporation platform and unparalleled scientific and regulatory expertise, they accelerate preclinical development for our partners. Their impact is profound as they identify critical flaws, provide tailored onsite support, expedite manufacturing process qualification, and confidently initiate investigational new drug submissions.

Each case study underscores their unwavering commitment and how MaxCyte's collaborative spirit and scientific excellence make a difference in advancing life-saving technology.

Listen to Andrew and Megan share how they help our partners

Featured

From Roadblocks to Breakthroughs, Unlocking Clinic-ready Efficiency

Andrew Mancini, PhD, Senior Field Applications Scientist

Andrew shares how his collaboration with a cell-therapy developer led to a 90% efficiency boost, enabling the developer to confidently proceed with clinical manufacturing.

Featured

Empowering CDMOs: A Critical Tech Transfer Rescue

Megan Embrey, PhD, Senior Field Applications Scientist

Hear how Megan identified a critical flaw in the technology transfer process from a customer to a CDMO. Her swift action ensured a timely resolution and improved standard operating procedures.

Our partners share why MaxCyte works for them

hp-quote-icon

The equipment is reliable, and the customer service is the best I've ever experienced in a biotech company.

Joshua Sasine, Assistant Professor of Medicine at Cedars-Sinai Medical Center

hp-quote-icon

User friendly interface, well established protocols, and (a) supportive MaxCyte team.

Akitsu Hotta, Associate Professor at the Center for iPS Cell Research and Application, Kyoto University

hp-quote-icon

We use (the) MaxCyte ATx for T-cell gene editing. It enables us to achieve high knockdown efficiency. Easy, convenient and reproducible.

Menggui Huang, Principal Scientist

hp-quote-icon

We discussed the optimization of electroporation conditions with MaxCyte researchers, who provided us with more than 15 optimization programs, and finally found the best one for the manufacture of genetically modified T cells. This experience helped us a lot in the development of our T-cell product, and we were very impressed with the kind and reliable discussions with the MaxCyte team.

Shigeki Yagyu, Professor at Shinshu University

hp-quote-icon

Without MaxCyte, we would not have been able to scale our process to the level needed for our clinical program. Compared to other platforms evaluated, with MaxCyte's large-scale, closed-system electroporation process, we are able to drive down COGS, derisk the process, and have a reliable unit operation for gene editing.

Director at a United States biotech

hp-quote-icon

With the continued support from research specialists that is included with purchase of the machine, we are confident in our ability to optimize our transfections. No other company offered this kind of support. The importance of this service cannot be understated as there is continual turnover in the lab.

Graduate student at a United States university

hp-quote-icon

For our lab, we are new to the technology, and so we wanted to partner with a company that offered great products and great customer service. They are willing to go the extra mile to help their customers with any questions or problems they may be having. They are generous with their time and patiently go through the training process with our team.

Joe Huey, Development Technologist I

hp-quote-icon

Expertise. Expertise combined with a scalable device. Expertise in the field.

Postdoctoral student at a United States university

hp-quote-icon

The technical representatives are knowledgeable and very eager to help and develop solutions in any endeavor. Also, they are very proactive with sharing new developments.

Scientist at a global biomedical company

hp-quote-icon

My company had chosen MaxCyte to meet both its research and GMP-scale electroporation needs.

Scientist at CRISPR Therapeutics

Hear more case studies

Alicia Roi-Marino case study video overlay
Flexibility for RUO or GMP with faith in a partner to speed development

Hear Alicia's story about advising a customer on their entire process, including culture conditions and mRNA design, to reach viabilities of over 90% while maintaining the freedom to work with the same platform under RUO or GMP requirements.

Overlay slide of Case Study: Support beyond electroporation—optimizing the whole process presentation
Support beyond electroporation—complete process development support increases efficiencies by 30%

Michelle explains how she supported her customer in implementing process improvements using complimentary technologies upstream and downstream of electroporation to achieve an additional 30% efficiency.

Nitin Kulkarni case study video overlay
Too many lost runs—improving cell viability and recovery to scale up into the clinic

Nitin describes how he observed his customer's processes after multiple lost runs and addressed cell viability using MaxCyte’s ExPERT platform to overcome lost runs while scaling up to move into the clinic to dose their first patients.

success-vid-1-500X266
From challenges to qualification - the story of a validation breakthrough

Hear from Joan as she shares how her dedication and scientific expertise helped a stealth-mode cell-therapy company overcome a critical challenge and successfully reach their next inflection point.

peter-thumb
Overcoming challenges in process scale-up

Listen to Peter tell how he helped a customer overcome challenges in scaling up their cell therapy process using our large-scale electroporation platform so that they could produce and cryopreserve one batch for multiple doses.

We are ready to partner with you

Request a consultation to discuss how our technology and exemplary, tailored support can accelerate your cell therapy development.

Contact an expert